Analyst Consensus ?
1 unmapped firm rating excluded from the percentages.
AstraZeneca PLC · AZN · FY2026 Q2 · Calendar Q3 2026
AstraZeneca’s supplied results show earnings resilience, with EPS above consensus and revenue slightly below it. The investment case remains dependent on pipeline execution, launches, and offsetting portfolio and pricing pressures.
Research this report with FN2. Free to start; review your question before sending.
Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
The current quarter delivered actual EPS of 2.63 versus 2.50 estimated and revenue of 15.384 billion versus 15.436 billion estimated. The supplied current-quarter transcript analysis was unavailable; prior-quarter analysis emphasized oncology and rare-disease growth, pipeline progress, and higher investment.
A current-quarter guidance change is not available in the supplied analysis. Prior-quarter full-year guidance was described as maintained, with mid- to high-single-digit revenue growth and low double-digit EPS growth.
Follow AZN with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 free1 unmapped firm rating excluded from the percentages.
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| UBS | Buy | Neutral | Upgrade | Feb 13, 2025 |
| Erste Group | Buy | Hold | Upgrade | Sep 11, 2024 |
| TD Cowen | Buy | Buy | Maintain | Aug 12, 2024 |
| Argus Research | Buy | Buy | Maintain | May 30, 2024 |
| BMO Capital | Outperform | Outperform | Maintain | Apr 26, 2024 |
| Deutsche Bank | Hold | Sell | Upgrade | Apr 16, 2024 |
| Jefferies | Hold | Buy | Downgrade | Jan 3, 2024 |
| SVB Leerink | Outperform | Outperform | Maintain | Nov 14, 2022 |
| DZ Bank | Hold | Sell | Upgrade | Feb 11, 2022 |
| Morgan Stanley | Overweight | Equal Weight | Upgrade | Dec 7, 2020 |
| Cowen & Co. | Outperform | Outperform | Maintain | Dec 2, 2019 |
| Investec | Hold | Buy | Downgrade | Nov 19, 2018 |
| Argus | Buy | Hold | Upgrade | May 5, 2018 |
| Leerink Swann | Market Perform | Market Perform | Maintain | Feb 6, 2018 |
| JP Morgan | Overweight | Neutral | Upgrade | Dec 29, 2017 |
| Bernstein | Outperform | Market Perform | Upgrade | Sep 22, 2017 |
| Liberum | Hold | Buy | Downgrade | Sep 14, 2017 |
| Credit Suisse | Neutral | Underperform | Upgrade | May 15, 2017 |
| Exane BNP Paribas | Neutral | Outperform | Downgrade | Sep 14, 2016 |
| Goldman Sachs | Sell | Neutral | Downgrade | Apr 11, 2016 |
| HBSC | Hold | Buy | Downgrade | Feb 8, 2016 |
| Oddo Securities | Neutral | Upgrade | Jan 26, 2016 | |
| Barclays | Equal Weight | Underweight | Upgrade | Jan 19, 2016 |
| HSBC | Buy | Hold | Upgrade | Sep 2, 2015 |
| Berenberg | Buy | Hold | Upgrade | Jul 2, 2015 |
| LBBW Research | Hold | Sell | Upgrade | May 19, 2015 |
| SEB Enskilda | Buy | Hold | Upgrade | Feb 3, 2015 |
| Danske Bank | Sell | Buy | Downgrade | May 5, 2014 |
| Panmure Gordon | Buy | Hold | Upgrade | Apr 29, 2014 |
| Panmure | Buy | Hold | Upgrade | Apr 29, 2014 |
| Societe Generale | Hold | Sell | Upgrade | Apr 28, 2014 |
| Kepler Cheuvreux | Hold | Reduce | Upgrade | Apr 28, 2014 |
| Citigroup | Buy | Neutral | Upgrade | Apr 22, 2014 |
| Bank of America | Underperform | Neutral | Downgrade | Mar 3, 2014 |
| B of A Securities | Underperform | Neutral | Downgrade | Mar 3, 2014 |
| Bryan Garnier | Neutral | Buy | Downgrade | Dec 20, 2013 |
| Nordea Equity | Buy | Sell | Upgrade | Sep 16, 2013 |
| Nordea | Buy | Sell | Upgrade | Sep 16, 2013 |
| Swedbank | Reduce | Sell | Maintain | Aug 2, 2013 |
| Natixis | Neutral | Reduce | Upgrade | Mar 22, 2013 |
| Pareto Securities | Sell | Hold | Downgrade | Oct 26, 2012 |
Upside is calculated against the persisted current price $174.35. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| HSBC | Analyst unavailable | $216 | $179.64 | +23.9% | Dec 10, 2025 |
| Morgan Stanley | Analyst unavailable | $206 | $180.34 | +18.2% | Dec 3, 2025 |
| Berenberg Bank | Luisa Hector | $194 | $141.64 | +11.3% | Jul 9, 2025 |
| BMO Capital | Etzer Darout | $176 | $162.38 | +0.9% | Nov 13, 2024 |
| BMO Capital | Etzer Darout | $178 | $159.88 | +2.1% | Sep 11, 2024 |
| Argus Research | John Eade | $170 | $153.68 | -2.5% | May 30, 2024 |
| BMO Capital | Etzer Darout | $164 | $153.48 | -5.9% | May 28, 2024 |
| Leerink Partners | Andrew Berens | $158 | $129.72 | -9.4% | Jul 12, 2023 |
| BMO Capital | Analyst unavailable | $164 | $139 | -5.9% | Jan 5, 2023 |
| Leerink Partners | Analyst unavailable | $156 | $130.18 | -10.5% | Nov 11, 2022 |
| Leerink Partners | Analyst unavailable | $150 | $134.34 | -14.0% | May 4, 2022 |
Track every rating change on AZN the moment it posts. Free to start.
Start freeAstraZeneca PLC operates as a global biopharmaceutical leader, dedicated to the entire process of bringing prescription medicines to market, from their initial discovery and development through manufacturing and commercialization. The company's extensive portfolio of treatments, including prominent examples like Tagrisso, Farxiga, and Symbicort, addresses critical areas such as cardiovascular, renal, metabolic, and oncological conditions. Furthermore, it provides essential solutions for COVID-19 and various rare diseases, with products like Vaxzevria and Soliris.…
| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| ASND Ascendis Pharma A/S | FY2026 Q3 · Calendar Q4 2026 | +38.7% | +3.0% | Ascendis Q3 growth broadens the story, while execution risks remain |
| ALC Alcon Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.2% | -2.3% | Alcon holds FY outlook as new launches meet IOL competition |
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-31. For educational purposes only; not investment advice.